223 related articles for article (PubMed ID: 25253587)
1. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
Tajti J; Csáti A; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
[TBL] [Abstract][Full Text] [Related]
2. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
3. Emerging target-based paradigms to prevent and treat migraine.
Silberstein SD
Clin Pharmacol Ther; 2013 Jan; 93(1):78-85. PubMed ID: 23212108
[TBL] [Abstract][Full Text] [Related]
4. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
5. PACAP38 and PAC
Rubio-Beltrán E; Correnti E; Deen M; Kamm K; Kelderman T; Papetti L; Vigneri S; MaassenVanDenBrink A; Edvinsson L;
J Headache Pain; 2018 Aug; 19(1):64. PubMed ID: 30088106
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for migraine treatment.
Giamberardino MA; Martelletti P
Expert Opin Emerg Drugs; 2015 Mar; 20(1):137-47. PubMed ID: 25547922
[TBL] [Abstract][Full Text] [Related]
7. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
9. Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects.
Tajti J; Szok D; Nagy-Grocz G; Tuka B; Petrovics-Balog A; Toldi J; Vecsei L
Curr Med Chem; 2017; 24(13):1332-1349. PubMed ID: 28245765
[TBL] [Abstract][Full Text] [Related]
10. Emerging migraine treatments and drug targets.
Olesen J; Ashina M
Trends Pharmacol Sci; 2011 Jun; 32(6):352-9. PubMed ID: 21459461
[TBL] [Abstract][Full Text] [Related]
11. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
Hougaard A; Tfelt-Hansen P
Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
[TBL] [Abstract][Full Text] [Related]
12. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.
Labruijere S; Ibrahimi K; Chan KY; Maassenvandenbrink A
Expert Opin Drug Discov; 2013 Nov; 8(11):1309-23. PubMed ID: 23962310
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin/PAC
Rees TA; Labastida-Ramírez A; Rubio-Beltrán E
Trends Pharmacol Sci; 2023 Oct; 44(10):651-663. PubMed ID: 37543479
[TBL] [Abstract][Full Text] [Related]
15. CGRP antagonists and antibodies for the treatment of migraine.
Vécsei L; Szok D; Csáti A; Tajti J
Expert Opin Investig Drugs; 2015 Jan; 24(1):31-41. PubMed ID: 25219387
[TBL] [Abstract][Full Text] [Related]
16. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatment for chronic migraine and refractory chronic migraine.
Lionetto L; Negro A; Palmisani S; Gentile G; Del Fiore MR; Mercieri M; Simmaco M; Smith T; Al-Kaisy A; Arcioni R; Martelletti P
Expert Opin Emerg Drugs; 2012 Sep; 17(3):393-406. PubMed ID: 22862686
[TBL] [Abstract][Full Text] [Related]
18. New insights into the molecular actions of serotonergic antimigraine drugs.
Durham PL; Russo AF
Pharmacol Ther; 2002; 94(1-2):77-92. PubMed ID: 12191595
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for migraine treatment: an update.
Lambru G; Andreou AP; Guglielmetti M; Martelletti P
Expert Opin Emerg Drugs; 2018 Dec; 23(4):301-318. PubMed ID: 30484333
[No Abstract] [Full Text] [Related]
20. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
